Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness and Safety of Tildrakizumab for Patients with Moderate to Severe Genital Psoriasis

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying moderate to severe genital psoriasis, a skin condition that causes red, scaly patches in the genital area. The study will evaluate the effectiveness and safety of a medication called tildrakizumab, which is given as an injection under the skin. Participants in the study will receive either tildrakizumab or a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to assess how well tildrakizumab works in reducing the symptoms of genital psoriasis over a period of 16 weeks. Participants will be randomly assigned to receive either the medication or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The main goal is to see if tildrakizumab can help clear the skin or significantly reduce the severity of the psoriasis compared to the placebo.

Throughout the study, participants will have regular check-ups to monitor their progress and any side effects. The study will last for a total of 52 weeks, allowing researchers to gather comprehensive data on the long-term effects and safety of tildrakizumab. This research aims to provide valuable insights into the treatment of moderate to severe genital psoriasis and potentially improve the quality of life for those affected by this condition.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be asked to provide written informed consent. This means you agree to participate after understanding the purpose and risks of the trial.

    You must be at least 18 years old and have a diagnosis of moderate to severe genital psoriasis. This condition should not be well controlled with topical treatments, or you should be intolerant to such treatments.

  2. Step 2

    Initial assessments

    Before starting the treatment, a physical examination will be conducted to ensure your health is within acceptable limits, except for psoriasis.

    Women of childbearing potential will undergo a pregnancy test to confirm a negative result before the first dose of the study medication.

  3. Step 3

    Treatment phase

    You will receive **tildrakizumab**, a medication administered through a subcutaneous injection, which means it is injected under the skin.

    The study will compare **tildrakizumab** to a placebo, which is a substance with no active medication, over a period of 16 weeks.

  4. Step 4

    Monitoring and follow-up

    Throughout the study, your condition will be monitored regularly to evaluate the effectiveness and safety of the treatment.

    The primary goal is to see if there is a significant improvement in your psoriasis condition, measured by a specific scoring system.

  5. Step 5

    End of study

    At the end of the 16-week period, your progress will be assessed to determine the impact of the treatment.

    The study aims to find out if **tildrakizumab** is more effective than the placebo in treating moderate to severe genital psoriasis.

Who can join the trial?

9 criteria

  • Ability to understand the purpose and risks of the trial, willingness and ability to follow the study rules, and provide written consent to participate.
  • Must be at least 18 years old at the time of giving consent.
  • Have a diagnosis of moderate to severe genital psoriasis at the start of the study, which means a specific score of 3 or higher on a scale used by doctors.
  • Have non-genital plaque psoriasis covering at least 1% of the body at the start of the study. Plaque psoriasis is a skin condition that causes red, scaly patches.
  • Have genital psoriasis that is not well controlled with creams or ointments, or cannot use these treatments due to side effects.
  • Must have a negative test for tuberculosis (TB) within 4 weeks before starting the study medication. TB is a serious lung infection. If the test is positive, additional checks and treatments must be completed as per local guidelines.
  • Undergo a physical examination that shows normal or acceptable results before the first dose of the study medication.
  • For women who can become pregnant, a negative pregnancy test is required at the start of the study and within 24 hours before the first dose of the study medication.
  • Must be in good health overall, except for psoriasis, as determined by the study doctor based on medical history, physical examination, and lab tests.

Who cannot join the trial?

10 criteria

  • Patients with any other skin conditions that might interfere with the study results.
  • Patients who have used any other treatments for psoriasis recently that might affect the study results.
  • Patients with a history of severe allergic reactions to any of the ingredients in the study medication.
  • Patients who are currently participating in another clinical trial.
  • Patients with any serious health conditions that might make it unsafe for them to participate.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a history of drug or alcohol abuse.
  • Patients who have received any live vaccines recently.
  • Patients with any infections that are not well controlled.
  • Patients who have had cancer in the past, except for certain types of skin cancer.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Tildrakizumab is a medication used in this clinical trial to treat moderate to severe genital psoriasis. It is given as an injection under the skin. Tildrakizumab works by targeting a specific protein in the body that causes inflammation and is involved in the development of psoriasis. By blocking this protein, the medication helps to reduce the symptoms of psoriasis, such as redness, scaling, and itching, and can improve the appearance of the skin. This trial aims to evaluate how effective and safe Tildrakizumab is for people with this condition.

What is already known about the treatment

Tildrakizumab – Tildrakizumab is administered as an injection under the skin, known as subcutaneous administration. It is currently being studied in clinical trials for its effectiveness in treating moderate to severe genital psoriasis. The main therapeutic use of tildrakizumab is to help reduce the symptoms of this skin condition, which can include redness, irritation, and discomfort in the genital area. At the molecular level, tildrakizumab works by targeting a specific protein in the immune system called interleukin-23 (IL-23), which plays a role in inflammation and the development of psoriasis. It is classified as a monoclonal antibody, a type of medication designed to target specific proteins in the body.

Investigated diseases

Genital Psoriasis – Genital psoriasis is a chronic skin condition characterized by red, inflamed patches on the skin around the genital area. It is a form of psoriasis that specifically affects the genital region, causing discomfort and irritation. The condition can lead to itching, burning, and soreness, which may be exacerbated by friction or sweating. The skin lesions may appear as smooth, shiny, or scaly patches, differing from the typical thick, scaly plaques seen in other types of psoriasis. The progression of genital psoriasis can vary, with periods of flare-ups and remissions. It is important to note that while genital psoriasis can be uncomfortable, it is not contagious.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-515672-12-00Protocol codeTILD-24-01Estimated enrolment237 patientsSponsorSun Pharmaceutical Industries Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).